Breaking News Instant updates and real-time market news.

DD

DuPont

$66.97

0.6 (0.90%)

, DOW

Dow Chemical

$51.83

0.1 (0.19%)

06:16
10/03/16
10/03
06:16
10/03/16
06:16

EU regulators resume DuPont, Dow Chemical probe, Reuters reports

The European Commission has resumed its probe into the proposed $130B merger between Dow Chemical (DOW) and DuPont (DD) after halting the investigation in early September, Reuters reports. EU regulators will now decide on whether to approve the deal by February 6 after the companies provided important information requested by the commission. The regulator is also investigating a deal between Syngenta (SYT) and ChemChina as well as Bayer's (BAYRY) proposed purchase of Monsanto (MON). Reference Link

DD

DuPont

$66.97

0.6 (0.90%)

DOW

Dow Chemical

$51.83

0.1 (0.19%)

SYT

Syngenta

$87.60

-0.13 (-0.15%)

BAYRY

Bayer

$100.50

2.54 (2.59%)

MON

Monsanto

$102.20

0.41 (0.40%)

  • 05

    Oct

DD DuPont
$66.97

0.6 (0.90%)

07/06/16
SUSQ
07/06/16
NO CHANGE
SUSQ
Jury ruling a significant setback for Chemours, says Susquehanna
After a jury found that DuPont (DD) is liable in a case evaluating whether drinking water tainted with C8, a chemical used in the manufacturing of Teflon, caused a plaintiff's testicular cancer, Susquehanna called the ruling a significant setback for Chemours (CC). The jury not only awarded compensatory damages, but also determined that punitive damages are warranted, noted the firm, which pointed out that Chemours is the real party at risk, as it must indemnify DuPont for all of these PFOA litigation damages, with this trial representing only the third of 3,512 personal injury and 30 wrongful death cases facing the companies. Chemours shares are near their session lows, down about 19% in late afternoon trading following news of the jury ruling.
06/28/16
06/28/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on the today's top five analyst downgrades with this list compiled by The Fly: 1. Dow Chemical (DOW) downgraded to Neutral from Overweight at JPMorgan by analyst Jeffrey Zekauskas, citing a lack of near term upside potential amid rising risks of contraction in the major economic regions. Under weakening economic conditions, the market is likely to ask for a higher risk premium or margin of safety in investing in Dow Chemical, Zekauskas said. He cut his price target for the shares to $50 from $57. The analyst also downgraded DuPont (DD) to Neutral from Overweight this morning and lowered his price target for shares to $64 from $73. 2. Tesla (TSLA) downgraded to Hold from Buy at Argus by analyst Bill Selesky, citing the company's "ill-timed" bid to acquire SolarCity (SCTY). The acquisition offer comes at an "inappropriate time" for Tesla, given the company is still struggling to become profitable and it likely lengthens the time it would take for Tesla to do so, Selesky tells investors. The proposed acquisition adds a new level of meaningful risk to Tesla operations as well as potential dilution, the analyst added. 3. Mobileye (MBLY) downgraded to Neutral from Buy at Goldman by analyst Alexander Duval, citing the greater than 60% rise in the shares since February. The analyst remains positive on Mobileye's long-term prospects. He lowered his price target for the shares to $40 from $45. The developer of advanced driver assistance systems closed yesterday down $1.91 to $39.79. 4. WABCO (WBC) downgraded to Neutral from Overweight at Piper Jaffray by analyst Alexander Potter, saying the company has the highest European exposure in his coverage universe at 55% of 2015 revenue. With all the uncertainty in Europe following the Brexit vote, it's hard to trust out-year estimates, Potter tells investors in a research note. He cut his price target for WABCO shares to $94 from $124. Potter this morning also downgraded Navistar (NAV) to Neutral from Overweight and Meritor (MTOR) to Underweight from Neutral. WABCO was also downgraded to Neutral from Buy at Goldman this morning. Analyst Steve Song, who lowered his price target to $95 from $105, cut WABCO 2017-18 earnings estimates given WABCO's European truck market exposure, which is 60% of sales. 5. DISH (DISH) downgraded to Sell from Neutral at MoffettNathanson. The firm believes that DISH's ability to monetize its spectrum is limited, since none of the major telecom companies has enough funds to buy all or most of the spectrum. The firm thinks that many on the Street may be overestimating the value of the company's spectrum. It expects "downward pressure" on the stock to increase as investors begin to question whether DISH can sell its spectrum. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/06/16
BERN
07/06/16
NO CHANGE
BERN
Dow Chemical, DuPont valuation attractive even in a recession, says Bernstein
Bernstein reports that some investors are worried that Brexit will trigger a recession, and have noted that the shares of Dow (DOW) and DuPont (DD) dove 845 and 64%, respectively, from February 2008 through February 2009. However, the firm says that Dow had just acquired Rohm & Haas before the recession and barely escaped bankruptcy, while the U.S. was a high cost producer of ethylene in 2008 and has subsequently become a low cost producer of the product. Bernstein estimates that , following the planned merger of Dow and DuPont, the combined company's EBITDA would reach $15.5B in 2018 if a recession occurs, The firm says that this corresponds to an attractive EBITDA multiple of 8,.5.
08/31/16
BERN
08/31/16
NO CHANGE
BERN
Potash, Agrium deal would be very logical, says Bernstein
After Bloomberg reported that Potash (POT) and Agirum (AGU) are in advanced talks about merging, Bernstein analyst Jonas Oxgaard says that the merger would "make a lot of sense." He predicts that the deal would be a merger of equals that would be similar to the merger between Dow Chemical (DOW) and DuPont (DD). The analyst thinks there is a high likelihood of a deal taking place, and he keeps Outperform ratings on Potash and Agrium.
DOW Dow Chemical
$51.83

0.1 (0.19%)

07/29/16
JPMS
07/29/16
UPGRADE
Target $60
JPMS
Overweight
Dow Chemical upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Jeffrey Zekauskas upgraded Dow Chemical to Overweight saying global demand is "holding up generally well" following the company's Q2 results. He continues to believe that Dow/DuPont "will be a large free cash generator." The analyst raised his price target for the shares to $60 from $50.
07/29/16
07/29/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Dow Chemical (DOW) upgraded to Overweight from Neutral at JPMorgan with analyst Jeffrey Zekauskas saying global demand is "holding up generally well" following the company's second quarter results. 2. Molson Coors (TAP) upgraded to Buy from Neutral at Citi with analyst Wendy Nicholson citing the recent pullback in the shares. 3. Oshkosh (OSK) upgraded to Outperform from Sector Perform at RBC Capital with analyst Seth Weber saying he believes that the outlook for the company's Acess equipment and defense units has improved. 4. Pinnacle Foods (PF) upgraded to Buy from Hold at Stifel. 5. Western Digital (WDC) upgraded to Outperform from Neutral at Baird. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
SYT Syngenta
$87.60

-0.13 (-0.15%)

05/19/16
JEFF
05/19/16
NO CHANGE
Target $95
JEFF
Hold
Jefferies views Bayer buyout of Monsanto as 'relatively unlikely'
After Monsanto (MON) confirmed an unsolicited offer from Bayer (BAYRY), Jefferies analyst Laurence Alexander says he still believes a transaction is "relatively unlikely." The analyst expects Monsanto to object to Bayer's offer given its conviction in its research and development pipeline and longer-term competitive advantages. Shares of Syngenta (SYT) and DuPont (DD) could be pressured as regulatory scrutiny is likely to intensify should Monsanto get acquired, and BASF (BASFY) could sell off on investor concerns of a potential counter-bid, Alexander tells investors in a research note. On the other hand, he sees a potential Monsanto takeover as positive for shares of Novozymes (NVZMY) and FMC Corporation (FMC). "A further roll-up of 'specialty generic' agrichemical assets could entice capital, and FMC would be a plausible anchor for such an attempt," the analyst writes. He has a Hold rating on Monsanto with a $95 price target.
09/06/16
BERN
09/06/16
DOWNGRADE
BERN
Market Perform
Syngenta downgraded on valuation, anticipated deal delay at Bernstein
As noted earlier, Bernstein downgraded Syngenta to Market Perform from Outperform. As reasons for the downgrade, analyst Jeremy Redenius cited valuation and his belief that regulatory approvals for the company's acquisition by ChemChina could be delayed until 2017. Target to $92.20 from $90.20.
09/06/16
BERN
09/06/16
DOWNGRADE
BERN
Market Perform
Syngenta downgraded to Market Perform from Outperform at Bernstein
07/15/16
RAJA
07/15/16
UPGRADE
RAJA
Outperform
Syngenta upgraded to Outperform from Market Perform at Raymond James
BAYRY Bayer
$100.50

2.54 (2.59%)

09/15/16
BERN
09/15/16
NO CHANGE
BERN
Bayer acquisition negative, says Bernstein
After Bayer (BAYRY) agreed to buy Monsanto (MON), Bernstein analyst Jonas Oxgaard says he "continues to have a bearish view" of Monsanto's business, and he thinks that Monsanto's price exceeded the company's true value by about 60%. The analyst adds that the genetically modified products that Monsanto is developing "are not expected to command outsized premiums," while genetically modified seeds have nearly fully penetrated most of the Americas. He keeps an Underperform rating on Monsanto and an Outperform rating on Bayer.
09/21/16
JPMS
09/21/16
UPGRADE
Target $128
JPMS
Overweight
Monsanto upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Jeffrey Zekauskas upgraded Monsanto (MON) to Overweight saying the risk in the shares is "less than what the market assumes." The analyst believes downside risk should the takeover by Bayer (BAYRY) fail is around $100 per share. He notes that Monsanto shareholders would receive $128 per share should the acquisition close. Zekauskas raised his price target for Monsanto to $128 from $100.
09/26/16
BERN
09/26/16
UPGRADE
BERN
Market Perform
Monsanto upgraded on acquisition at Bernstein
As noted earlier, Bernstein upgraded Monsanto (MON) to Market Perform from Underperform. Analyst Jonas Oxgaard upgraded the stock after Bayer (BAYRY) agreed to buy Monsanto. However, he warned that "it's too early to tell" whether regulators will approve the deal, and he says that the risk is "skewed to the downside in the near-term." He recommends that investors avoid the stock for 6-9 months. Target to $105 from $90.
09/15/16
PIPR
09/15/16
NO CHANGE
Target $128
PIPR
Overweight
Piper has confidence in closing of Monsanto, Bayer merger
Piper Jaffray analyst Brett Wong raised his price target for Monsanto (MON) to $128 citing the takeover price paid by Bayer (BAYRY). The analyst views the offer price as lower than expected but has confidence regulatory approval will be granted since there is a minimal crossover between the two companies. He reiterates an Overweight rating on Monsanto.
MON Monsanto
$102.20

0.41 (0.40%)

09/27/16
GSCO
09/27/16
UPGRADE
GSCO
Neutral
Monsanto upgraded to Neutral from Sell at Goldman
09/26/16
BERN
09/26/16
UPGRADE
BERN
Market Perform
Monsanto upgraded to Market Perform from Underperform at Bernstein
09/21/16
09/21/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Monsanto (MON) upgraded to Overweight from Neutral at JPMorgan with analyst Jeffrey Zekauskas saying the risk in the shares is "less than what the market assumes." 2. Barclays (BCS) upgraded to Buy from Hold at HSBC citing the pending disposal of non-core businesses and resulting value creation. 3. Etsy (ETSY) upgraded to Buy from Neutral at Monness Crespi with the firm's analyst believing that Etsy shares can still move higher and sees a solid opportunity for upward revisions from improving conversion rates due to enhanced search and mobile functionality, expanding take rates, and advanced cross-boarder commerce capabilities with vendors. 4. Clovis (CLVS) upgraded to Outperform from Neutral at Credit Suisse with analyst Kennen MacKay saying the potential for a takeover "outweighs concerns surrounding patent life, limited experience in platinum resistant/refractory patients, and PARPi competition." 5. Jabil Circuit (JBL) upgraded to Buy from Neutral at UBS with analyst Steven Milunovich saying the company's cash flow is nearing an inflection amid an upturn in its Apple (AAPL) business. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

TFX

Teleflex

$184.01

-0.51 (-0.28%)

06:34
02/23/17
02/23
06:34
02/23/17
06:34
Earnings
Teleflex reports Q4 adjusted EPS $2.13, consensus $2.09 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

DORM

Dorman Products

$77.94

5.68 (7.86%)

06:34
02/23/17
02/23
06:34
02/23/17
06:34
Downgrade
Dorman Products rating change  »

Dorman Products…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZBRA

Zebra Technologies

$85.73

-0.95 (-1.10%)

06:33
02/23/17
02/23
06:33
02/23/17
06:33
Earnings
Zebra Technologies reports Q4 EPS $1.93, consensus $1.73 »

Reports Q4 revenue $942M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

WAAS

AquaVenture

$18.01

0.69 (3.98%)

06:33
02/23/17
02/23
06:33
02/23/17
06:33
Upgrade
AquaVenture rating change  »

AquaVenture upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

SAGE

SAGE Therapeutics

$61.93

-2.13 (-3.33%)

06:32
02/23/17
02/23
06:32
02/23/17
06:32
Hot Stocks
Breaking Hot Stocks news story on SAGE Therapeutics »

SAGE Therapeutics sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

SAGE

SAGE Therapeutics

$61.93

-2.13 (-3.33%)

06:31
02/23/17
02/23
06:31
02/23/17
06:31
Earnings
Breaking Earnings news story on SAGE Therapeutics »

SAGE Therapeutics reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

LB

Labarge

$58.13

0.43 (0.75%)

06:31
02/23/17
02/23
06:31
02/23/17
06:31
Recommendations
Labarge analyst commentary  »

L Brands selloff brings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

GE

General Electric

$30.09

-0.19 (-0.63%)

06:30
02/23/17
02/23
06:30
02/23/17
06:30
Periodicals
Suez in the running for General Electric's water unit, Reuters reports »

France's Suez is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

DLHC

DLH Holdings Corp.

$5.27

-0.08 (-1.50%)

06:30
02/23/17
02/23
06:30
02/23/17
06:30
Initiation
DLH Holdings Corp. initiated  »

DLH Holdings Corp.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CM

CIBC

$89.90

0.44 (0.49%)

06:28
02/23/17
02/23
06:28
02/23/17
06:28
Earnings
CIBC reports Q1 adjusted EPS C$2.89, consensus C$1.96 »

Reports Q1 loan loss…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMRE

Global Medical REIT

$8.48

0.06 (0.71%)

06:28
02/23/17
02/23
06:28
02/23/17
06:28
Initiation
Global Medical REIT initiated  »

Global Medical REIT…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TFX

Teleflex

$184.01

-0.51 (-0.28%)

06:25
02/23/17
02/23
06:25
02/23/17
06:25
Hot Stocks
Teleflex CEO Benson Smith retiring at end of 2017, succeeded by COO Liam Kelly »

Teleflex CEO Benson Smith…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

MBLY

Mobileye

$47.42

1.3 (2.82%)

06:22
02/23/17
02/23
06:22
02/23/17
06:22
Recommendations
Mobileye analyst commentary  »

Mobileye price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRI

Carter's

$83.58

-0.4 (-0.48%)

06:20
02/23/17
02/23
06:20
02/23/17
06:20
Hot Stocks
Carter's raises quarterly dividend 12% to 37c per share »

For payment on March 24…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

CRI

Carter's

$83.58

-0.4 (-0.48%)

06:19
02/23/17
02/23
06:19
02/23/17
06:19
Earnings
Carter's sees FY17 adjusted EPS growth 8%-10%, consensus $5.52 »

For fiscal 2017, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

CRI

Carter's

$83.58

-0.4 (-0.48%)

06:18
02/23/17
02/23
06:18
02/23/17
06:18
Earnings
Carter's sees Q1 adjusted EPS 80c-85c, consensus $1.14 »

For the first quarter of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

NVCR

Novocure

$7.15

-0.15 (-2.05%)

06:17
02/23/17
02/23
06:17
02/23/17
06:17
Hot Stocks
Novocure Chief Commercial Officer Peter Melnyk departing »

Novocure's Chief…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 02

    Mar

CS

Credit Suisse

$15.35

-0.13 (-0.84%)

06:17
02/23/17
02/23
06:17
02/23/17
06:17
Periodicals
Credit Suisse allocates $600M to expand Saudi Arabia business, Bloomberg says »

Credit Suisse is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

OUT

OUTFRONT Media

$26.89

-0.44 (-1.61%)

06:16
02/23/17
02/23
06:16
02/23/17
06:16
Downgrade
OUTFRONT Media rating change  »

OUTFRONT Media downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

CRI

Carter's

$83.58

-0.4 (-0.48%)

06:16
02/23/17
02/23
06:16
02/23/17
06:16
Hot Stocks
Breaking Hot Stocks news story on Carter's »

Carter's raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

EFOI

Energy Focus

$3.71

-0.21 (-5.36%)

06:16
02/23/17
02/23
06:16
02/23/17
06:16
Hot Stocks
Energy Focus sees Q1 restructuring charges of $1.1M »

As previously announced,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

CRI

Carter's

$83.58

-0.4 (-0.48%)

06:16
02/23/17
02/23
06:16
02/23/17
06:16
Earnings
Carter's reports Q4 adjusted EPS $1.79, consensus $1.67 »

Reports Q4 revenue $934M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

CMVT

Comverse

06:15
02/23/17
02/23
06:15
02/23/17
06:15
Periodicals
Former Comverse CEO faces sentencing in fraud case, Reuters reports »

Jacob "Kobi"…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFOI

Energy Focus

$3.71

-0.21 (-5.36%)

06:15
02/23/17
02/23
06:15
02/23/17
06:15
Recommendations
Energy Focus analyst commentary  »

Energy Focus reports Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

BAYRY

Bayer

$113.85

-1.15 (-1.00%)

, MON

Monsanto

$111.38

0.81 (0.73%)

06:13
02/23/17
02/23
06:13
02/23/17
06:13
Periodicals
Bayer looks to raise $19B in equity to fund proposed Monsanto deal, WSJ reports »

Bayer (BAYRY) is looking…

BAYRY

Bayer

$113.85

-1.15 (-1.00%)

MON

Monsanto

$111.38

0.81 (0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Mar

  • 01

    Apr

  • 26

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.